Stock DTC DEFENCE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Market Closed - Canadian Securities Exchange
Other stock markets
 03:51:24 2024-07-02 pm EDT 		5-day change 1st Jan Change
0.8 CAD 0.00% Intraday chart for Defence Therapeutics Inc. -4.76% -65.67%
Jun. 06 Defence Therapeutics Inc. Announces Publication of A Peer-Reviewed Study on the Anticancer Properties of Its Unconjugated AccuTOX CI
May. 29 Defence Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS
EQ
Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
NE
Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals
NE
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
EQ
Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin
NE
DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
EQ
Ellis Martin Report: Defence Therapeutics Inc. Dr. Moutih Rafei-Developing Vaccines and Platform Technologies for the Treatment of Cancer
AW
Ellis Martin Report: Defence Therapeutics Inc. (CNSX:DTC) Dr. Moutih Rafei-Developing Vaccines and Platform Technologies for the Treatment of Cancer
AQ
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
NE
DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
EQ
Defence Therapeutics Inc. Announces Publication of A Peer-Reviewed Study on the Anticancer Properties of Its Unconjugated AccuTOX
CI
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule
NE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
EQ
Defence Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
NE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
EQ
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
EQ
Defence Therapeutics Announces Successful Trial Against Pancreatic Cancer with its ARM-002 Anti-Cancer Vaccine
CI
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine
NE
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DTC Stock
  4. News Defence Therapeutics Inc.